In Vitro Maturation Is an Efficient Technique to Generate Oocytes and Should Be Considered in Combination With Cryopreservation of Ovarian Tissue for Preservation of Fertility in Women

2006 ◽  
Vol 24 (33) ◽  
pp. 5336-5337 ◽  
Author(s):  
Michael von Wolff ◽  
Thomas Strowitzki ◽  
Hans van der Ven ◽  
Markus Montag
Keyword(s):  
In Vitro Maturation ◽  
Ovarian Tissue ◽  
Efficient Technique ◽  
Preservation Of Fertility

In-vitro maturation of oocytes from ovarian tissue expands fertility preservation options

2011 ◽  
Vol 96 (3) ◽  
pp. S49
Author(s):  
L. Clark ◽  
W. Vitek ◽  
J. Witmyer ◽  
R. Hackett ◽  
S.A. Carson ◽  
...  
Keyword(s):  
Fertility Preservation ◽  
In Vitro Maturation ◽  
Ovarian Tissue

P–431 Human oocytes in-vitro maturation efficacy from infancy to adulthood – is there an optimal age?

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
G Karavani ◽  
P Wasserzug-Pash ◽  
T Mordechai-Daniel ◽  
M Klutstein ◽  
T Imbar
Keyword(s):  
Fertility Preservation ◽  
In Vitro Maturation ◽  
Ovarian Tissue ◽  
Age Groups ◽  
Ovarian Tissue Cryopreservation ◽  
Success Rates ◽  
Human Oocytes ◽  
Tertiary Center ◽  
Significant Difference

Abstract Study question Does human oocytes in-vitro maturation (IVM) effectiveness change throughout childhood, adolescence and adulthood in girls and women undergoing fertility preservation via ovarian tissue cryopreservation (OTC) prior to chemo-radiotherapy exposure? Summary answer The optimal age for IVM is from menarche to 25 years, while pre-menarche girls and women older than 30 years have extremely low maturation rates. What is known already In vitro maturation of oocytes from antral follicles seen during tissue harvesting is a fertility preservation technique with potential advantages over OTC, as mature frozen and later thawed oocyte used for fertilization poses decreased risk of malignant cells re-seeding, as compared to ovarian tissue implantation. We previously demonstrated that IVM performed following OTC in fertility preservation patients, even in pre-menarche girls, yields a fair amount of oocytes available for IVM and freezing for future use. Study design, size, duration A retrospective cohort study, evaluating IVM outcomes in chemotherapy naïve patients referred for fertility preservation by OTC that had oocyte collected from the medium with attempted IVM between 2003 and 2020 in a university affiliated tertiary center. Participants/materials, setting, methods A total of 133 chemotherapy naïve patients aged 1–35 years with attempted IVM were included in the study. The primary outcome was IVM rate in the different age groups – pre-menarche (1–5 years and ≥6 years), post-menarche (menarche–17 years), young adults (18–24 years) and adults (25–29 and 30–35 years). Comparison between paired groups for significant difference in the IVM rate parameter was done using the Tukey’s Studentized Range (HSD) Test. Main results and the role of chance A gradual increase in mean IVM rate was demonstrated in the age groups over 1 to 25 years (4.6% (1–5 years), 23.8% (6 years to menarche) and 28.4% (menarche to 17 years), with a peak of 38.3% in the 18–24 years group, followed by a decrease in the 25–29 years group (19.3%), down to a very low IVM rate (8.9%) in the 30–35 years group. A significant difference in IVM rates was noted between the age extremes – the very young (1–5 years) and the oldest (30–35 years) groups, as compared with the 18–24-year group (p < 0.001). Number of oocytes matured, percent of patients with matured oocytes and overall maturation rate differed significantly (p < 0.001). Limitations, reasons for caution Data regarding ovarian reserve evaluation was not available for most of the patients, due to our pre-op OTC procedures protocol. None of our patients have used their frozen in-vitro matured oocytes, as such further implications of age on in-vitro matured oocytes quality and implantation potential has yet to be evaluated. Wider implications of the findings: Our finding of extremely low success rates in those very young (under 6 years) and older (≥30 years) patients suggest that IVM of oocyte retrieved during OTC prior to chemotherapy should not be attempted in these age group. Trial registration number N/A

Recovery of fertility from adult ovarian tissue transplanted into week-old Japanese quail chicks

2015 ◽  
Vol 27 (2) ◽  
pp. 281 ◽  
Author(s):  
Jianan Liu ◽  
Kimberly M. Cheng ◽  
Frederick G. Silversides
Keyword(s):  
Japanese Quail ◽  
Sexual Maturity ◽  
Egg Production ◽  
In Vitro Maturation ◽  
Ovarian Tissue ◽  
Reproductive Potential ◽  
Special Importance ◽  
Old Japanese ◽  
Cryopreserved Ovarian Tissue

Fertility of cryopreserved ovarian tissue from immature chickens and Japanese quail has been recovered by transplantation. This is of special importance for non-mammalian vertebrates in which cryopreservation and in vitro maturation of oocytes are challenging because their oogenesis is characterised by vitellogenesis. This study tested whether fertility of adult quail ovarian tissue could be recovered by transplantation. Ovaries were isolated from mature Japanese quail hens, trimmed, cut into 3- to 4-mm2 pieces and transplanted into ovariectomised, week-old chicks. Recipients were administered an immunosuppressant for two weeks. Ten of 12 recipients survived until sexual maturity and seven laid eggs, but all stopped laying by 17 weeks of age. The age at first egg of recipients laying eggs (75.7 ± 4.2 days) was greater than that of untreated hens (51.8 ± 1.7 days) and egg production of recipients during the laying period (21.7 ± 5.7) was less than that of untreated hens (60.8 ± 3.5). Recipients were paired with males from the WB line for test mating. Only two hens laid eggs during the test period but both produced 100% donor-derived offspring. This research demonstrated that the reproductive potential of ovarian tissue from adult quail hens can be restored by transplantation.

First in vitro maturation (IVM) of oocytes retrieved from extracorporeal ovarian tissue aspiration leading to livebirth

2014 ◽  
Vol 102 (3) ◽  
pp. e126
Author(s):  
P.S. Uzelac ◽  
A.A. Delaney ◽  
G.L. Christensen ◽  
C.H.L. Bohler ◽  
S.T. Nakajima
Keyword(s):  
In Vitro Maturation ◽  
Ovarian Tissue

scholarly journals OVARIAN TISSUE OOCYTES IN VITRO MATURATION AS A METHOD OF FERTILITY PRESERVATION IN PATIENTS WITH GYNECOLOGICAL CANCER: A PILOT STUDY

2021 ◽  
Vol 116 (3) ◽  
pp. e2-e3
Author(s):  
Anastasia Kirillova ◽  
Ekaterina Bunyaeva ◽  
Nona Mishieva ◽  
Aydar Abubakirov ◽  
Johan E.J. Smitz
Keyword(s):  
Pilot Study ◽  
Fertility Preservation ◽  
In Vitro Maturation ◽  
Ovarian Tissue ◽  
Gynecological Cancer

scholarly journals New methods for the recovery of oocytes from bovine ovarian tissue in relation to in vitro maturation and fertilization.

1987 ◽  
Vol 33 (4) ◽  
pp. 188-192 ◽  
Author(s):  
Setsuo IWASAKI ◽  
Tomohiro KONO ◽  
Tatsuo NAKAHARA ◽  
Yasuo SHIOYA ◽  
Moriyuki FUKUSHIMA ◽  
...  
Keyword(s):  
In Vitro Maturation ◽  
Ovarian Tissue ◽  
New Methods

Live births following fertility preservation using in-vitro maturation of ovarian tissue oocytes

2020 ◽  
Vol 35 (9) ◽  
pp. 2026-2036 ◽  
Author(s):  
Ingrid Segers ◽  
Erlisa Bardhi ◽  
Ileana Mateizel ◽  
Ellen Van Moer ◽  
Rik Schots ◽  
...  
Keyword(s):  
Fertility Preservation ◽  
Live Birth ◽  
Study Design ◽  
In Vitro Maturation ◽  
Ovarian Tissue ◽  
Added Value ◽  
Ovarian Tissue Cryopreservation ◽  
Small Series ◽  
Valuable Adjunct

Abstract STUDY QUESTION Can oocytes extracted from excised ovarian tissue and matured in vitro be a useful adjunct for urgent fertility preservation (FP)? SUMMARY ANSWER Ovarian tissue oocyte in-vitro maturation (OTO-IVM) in combination with ovarian tissue cryopreservation (OTC) is a valuable adjunct technique for FP. WHAT IS KNOWN ALREADY Despite the impressive progress in the field, options for FP for cancer patients are still limited and, depending on the technique, clinical outcome data are still scarce. STUDY DESIGN, SIZE, DURATION This was a retrospective cohort study conducted at a university hospital-affiliated fertility clinic between January 2012 and May 2019. PARTICIPANTS/MATERIALS, SETTING, METHODS The study included 77 patients who underwent unilateral oophorectomy for OTC. Cumulus-oocyte complexes (COCs) obtained during ovarian tissue processing were matured in vitro for 28–42 h. Oocytes reaching metaphase II stage were vitrified or inseminated for embryo vitrification. MAIN RESULTS AND THE ROLE OF CHANCE Overall, 1220 COCs were collected. The mean oocyte maturation rate was 39% ± 23% (SD). There were 64 patients who had vitrification of oocytes (6.7 ± 6.3 oocytes per patient). There were 13 patients who had ICSI of mature oocytes after IVM, with 2.0 ± 2.0 embryos vitrified per patient. Twelve patients have returned to the clinic with a desire for pregnancy. For seven of these, OTO-IVM material was thawed. Two patients had OTO-IVM oocytes warmed, with survival rates of 86% and 60%. After ICSI, six oocytes were fertilised in total, generating three good quality embryos for transfer, leading to a healthy live birth for one patient. In five patients, for whom a mean of 2.0 ± 0.8 (SD) embryos had been vitrified, seven embryos were warmed in total: one embryo did not survive the warming process; two tested genetically unsuitable for transfer; and four were transferred in separate cycles to three different patients, resulting in two healthy babies. In this small series, the live birth rate per patient after OTO-IVM, ICSI and embryo transfer was 43%. LIMITATIONS, REASONS FOR CAUTION The retrospective study design and the limited sample size should be considered when interpreting results. WIDER IMPLICATIONS OF THE FINDINGS The results of the study illustrate the added value of OTO-IVM in combination with OTC. We report the first live birth following the use of this appended technique combined with oocyte vitrification. STUDY FUNDING/COMPETING INTEREST(S) No external funding was used for this study. M.D.V. reports honoraria for lectures in the last 2 years from MSD and Ferring, outside the submitted work, as well as grant support from MSD. The other authors have nothing to declare. TRIAL REGISTRATION NUMBER N/A

Sign in / Sign up

Export Citation Format

Share Document